APO Research
Talk to an analyst

APO RESEARCH · REPORT

lrinotecan

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global lrinotecan Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry Researchlrinotecan Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal lrinotecan Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal lrinotecan Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal lrinotecan Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal lrinotecan Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global lrinotecan market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for lrinotecan is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for lrinotecan is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for lrinotecan is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the lrinotecan market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the lrinotecan market include Actiza Pharmaceutical, Cipla, Getwell, Salius, Taj Pharma, West-ward Pharmaceuticals, Pfizer and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global lrinotecan market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of lrinotecan and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents lrinotecan sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the lrinotecan market size, projected growth trends, production technologies, key applications, and end-use industries.

lrinotecan Segment by Company

Actiza Pharmaceutical

Cipla

Getwell

Salius

Taj Pharma

West-ward Pharmaceuticals

Pfizer

Teva

lrinotecan Segment by Type

Irinotecan Hydrochloride Injection 40mg

Irinotecan Hydrochloride Injection 100mg

Others

lrinotecan Segment by Application

Clinic

Hospital

Others

lrinotecan Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global lrinotecan status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions lrinotecan market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify lrinotecan significant trends, drivers, influence factors in global and regions.

6. To analyze lrinotecan competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global lrinotecan market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of lrinotecan and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of lrinotecan.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the lrinotecan market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global lrinotecan industry.

Chapter 3: Detailed analysis of lrinotecan manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of lrinotecan in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of lrinotecan in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. lrinotecan Industry Trends Table 2. lrinotecan Industry Drivers Table 3. lrinotecan Industry Opportunities and Challenges Table 4. lrinotecan Industry Restraints Table 5. Global lrinotecan Revenue by Company (US$ Million) & (2021-2026) Table 6. Global lrinotecan Revenue Share by Company (2021-2026) Table 7. Global lrinotecan Sales Volume by Company (k units) & (2021-2026) Table 8. Global lrinotecan Sales Volume Share by Company (2021-2026) Table 9. Global lrinotecan Average Price (US$/unit) of Company (2021-2026) Table 10. Global lrinotecan Company Ranking, (2024-2026) & (USD Million) Table 11. Global lrinotecan Key Company Manufacturing Base & Headquarters Table 12. Global lrinotecan Company, Product Type & Application Table 13. Global lrinotecan Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global lrinotecan by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Irinotecan Hydrochloride Injection 40mg Table 18. Significant Companies of Irinotecan Hydrochloride Injection 100mg Table 19. Significant Companies of Others Table 20. Global lrinotecan Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global lrinotecan Sales Volume by Type (2021-2026) & (k units) Table 22. Global lrinotecan Sales Volume by Type (2027-2032) & (k units) Table 23. Global lrinotecan Sales Volume Share by Type (2021-2026) Table 24. Global lrinotecan Sales Volume Share by Type (2027-2032) Table 25. Global lrinotecan Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global lrinotecan Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global lrinotecan Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global lrinotecan Sales Value Share by Type (2021-2026) Table 29. Global lrinotecan Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Clinic Table 31. Significant Companies of Hospital Table 32. Significant Companies of Others Table 33. Global lrinotecan Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global lrinotecan Sales Volume by Application (2021-2026) & (k units) Table 35. Global lrinotecan Sales Volume by Application (2027-2032) & (k units) Table 36. Global lrinotecan Sales Volume Share by Application (2021-2026) Table 37. Global lrinotecan Sales Volume Share by Application (2027-2032) Table 38. Global lrinotecan Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global lrinotecan Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global lrinotecan Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global lrinotecan Sales Value Share by Application (2021-2026) Table 42. Global lrinotecan Sales Value Share by Application (2027-2032) Table 43. Global lrinotecan Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global lrinotecan Sales by Region (2021-2026) & (k units) Table 45. Global lrinotecan Sales Market Share by Region (2021-2026) Table 46. Global lrinotecan Sales by Region (2027-2032) & (k units) Table 47. Global lrinotecan Sales Market Share by Region (2027-2032) Table 48. Global lrinotecan Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global lrinotecan Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global lrinotecan Sales Value Share by Region (2021-2026) Table 51. Global lrinotecan Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global lrinotecan Sales Value Share by Region (2027-2032) Table 53. Global lrinotecan Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global lrinotecan Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global lrinotecan Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global lrinotecan Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global lrinotecan Sales by Country (2021-2026) & (k units) Table 58. Global lrinotecan Sales Market Share by Country (2021-2026) Table 59. Global lrinotecan Sales by Country (2027-2032) & (k units) Table 60. Global lrinotecan Sales Market Share by Country (2027-2032) Table 61. Global lrinotecan Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global lrinotecan Sales Value Market Share by Country (2021-2026) Table 63. Global lrinotecan Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global lrinotecan Sales Value Market Share by Country (2027-2032) Table 65. Actiza Pharmaceutical Company Information Table 66. Actiza Pharmaceutical Business Overview Table 67. Actiza Pharmaceutical lrinotecan Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Actiza Pharmaceutical lrinotecan Product Portfolio Table 69. Actiza Pharmaceutical Recent Development Table 70. Cipla Company Information Table 71. Cipla Business Overview Table 72. Cipla lrinotecan Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Cipla lrinotecan Product Portfolio Table 74. Cipla Recent Development Table 75. Getwell Company Information Table 76. Getwell Business Overview Table 77. Getwell lrinotecan Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Getwell lrinotecan Product Portfolio Table 79. Getwell Recent Development Table 80. Salius Company Information Table 81. Salius Business Overview Table 82. Salius lrinotecan Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Salius lrinotecan Product Portfolio Table 84. Salius Recent Development Table 85. Taj Pharma Company Information Table 86. Taj Pharma Business Overview Table 87. Taj Pharma lrinotecan Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Taj Pharma lrinotecan Product Portfolio Table 89. Taj Pharma Recent Development Table 90. West-ward Pharmaceuticals Company Information Table 91. West-ward Pharmaceuticals Business Overview Table 92. West-ward Pharmaceuticals lrinotecan Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. West-ward Pharmaceuticals lrinotecan Product Portfolio Table 94. West-ward Pharmaceuticals Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer lrinotecan Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Pfizer lrinotecan Product Portfolio Table 99. Pfizer Recent Development Table 100. Teva Company Information Table 101. Teva Business Overview Table 102. Teva lrinotecan Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Teva lrinotecan Product Portfolio Table 104. Teva Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. lrinotecan Distributors List Table 108. lrinotecan Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. lrinotecan Product Image Figure 2. Global lrinotecan Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global lrinotecan Sales Value (2021-2032) & (US$ Million) Figure 4. Global lrinotecan Sales (2021-2032) & (k units) Figure 5. Global lrinotecan Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global lrinotecan Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Irinotecan Hydrochloride Injection 40mg Image Figure 10. Irinotecan Hydrochloride Injection 100mg Image Figure 11. Others Image Figure 12. Global lrinotecan Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global lrinotecan Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global lrinotecan Sales Volume Share by Type (2021-2032) Figure 15. Global lrinotecan Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global lrinotecan Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global lrinotecan Sales Value Share by Type (2021-2032) Figure 18. Clinic Image Figure 19. Hospital Image Figure 20. Others Image Figure 21. Global lrinotecan Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global lrinotecan Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global lrinotecan Sales Volume Share by Application (2021-2032) Figure 24. Global lrinotecan Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global lrinotecan Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global lrinotecan Sales Value Share by Application (2021-2032) Figure 27. Global lrinotecan Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global lrinotecan Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global lrinotecan Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global lrinotecan Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America lrinotecan Sales Value (2021-2032) & (US$ Million) Figure 32. North America lrinotecan Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe lrinotecan Sales Value (2021-2032) & (US$ Million) Figure 34. Europe lrinotecan Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific lrinotecan Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific lrinotecan Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America lrinotecan Sales Value (2021-2032) & (US$ Million) Figure 38. South America lrinotecan Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa lrinotecan Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa lrinotecan Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt lrinotecan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt lrinotecan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt lrinotecan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. lrinotecan Value Chain Figure 126. Manufacturing Cost Structure Figure 127. lrinotecan Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Irinotecan Hydrochloride Injection 40mg
  • Irinotecan Hydrochloride Injection 100mg
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Actiza Pharmaceutical
  • Cipla
  • Getwell
  • Salius
  • Taj Pharma
  • West-ward Pharmaceuticals
  • Pfizer
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global lrinotecan Sales Value (2021-2032)
  4. 1.2.2 Global lrinotecan Sales Volume (2021-2032)
  5. 1.2.3 Global lrinotecan Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 lrinotecan Market Dynamics
  1. 2.1 lrinotecan Industry Trends
  2. 2.2 lrinotecan Industry Drivers
  3. 2.3 lrinotecan Industry Opportunities and Challenges
  4. 2.4 lrinotecan Industry Restraints
3 lrinotecan Market by Company
  1. 3.1 Global lrinotecan Company Revenue Ranking in 2025
  2. 3.2 Global lrinotecan Revenue by Company (2021-2026)
  3. 3.3 Global lrinotecan Sales Volume by Company (2021-2026)
  4. 3.4 Global lrinotecan Average Price by Company (2021-2026)
  5. 3.5 Global lrinotecan Company Ranking (2024-2026)
  6. 3.6 Global lrinotecan Company Manufacturing Base and Headquarters
  7. 3.7 Global lrinotecan Company Product Type and Application
  8. 3.8 Global lrinotecan Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global lrinotecan Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 lrinotecan Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 lrinotecan Market by Type
  1. 4.1 lrinotecan Type Introduction
  2. 4.1.1 Irinotecan Hydrochloride Injection 40mg
  3. 4.1.2 Irinotecan Hydrochloride Injection 100mg
  4. 4.1.3 Others
  5. 4.2 Global lrinotecan Sales Volume by Type
  6. 4.2.1 Global lrinotecan Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global lrinotecan Sales Volume by Type (2021-2032)
  8. 4.2.3 Global lrinotecan Sales Volume Share by Type (2021-2032)
  9. 4.3 Global lrinotecan Sales Value by Type
  10. 4.3.1 Global lrinotecan Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global lrinotecan Sales Value by Type (2021-2032)
  12. 4.3.3 Global lrinotecan Sales Value Share by Type (2021-2032)
5 lrinotecan Market by Application
  1. 5.1 lrinotecan Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global lrinotecan Sales Volume by Application
  6. 5.2.1 Global lrinotecan Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global lrinotecan Sales Volume by Application (2021-2032)
  8. 5.2.3 Global lrinotecan Sales Volume Share by Application (2021-2032)
  9. 5.3 Global lrinotecan Sales Value by Application
  10. 5.3.1 Global lrinotecan Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global lrinotecan Sales Value by Application (2021-2032)
  12. 5.3.3 Global lrinotecan Sales Value Share by Application (2021-2032)
6 lrinotecan Regional Sales and Value Analysis
  1. 6.1 Global lrinotecan Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global lrinotecan Sales by Region (2021-2032)
  3. 6.2.1 Global lrinotecan Sales by Region: 2021-2026
  4. 6.2.2 Global lrinotecan Sales by Region (2027-2032)
  5. 6.3 Global lrinotecan Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global lrinotecan Sales Value by Region (2021-2032)
  7. 6.4.1 Global lrinotecan Sales Value by Region: 2021-2026
  8. 6.4.2 Global lrinotecan Sales Value by Region (2027-2032)
  9. 6.5 Global lrinotecan Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America lrinotecan Sales Value (2021-2032)
  12. 6.6.2 North America lrinotecan Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe lrinotecan Sales Value (2021-2032)
  15. 6.7.2 Europe lrinotecan Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific lrinotecan Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific lrinotecan Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America lrinotecan Sales Value (2021-2032)
  21. 6.9.2 South America lrinotecan Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa lrinotecan Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa lrinotecan Sales Value Share by Country, 2025 VS 2032
7 lrinotecan Country-level Sales and Value Analysis
  1. 7.1 Global lrinotecan Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global lrinotecan Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global lrinotecan Sales by Country (2021-2032)
  4. 7.3.1 Global lrinotecan Sales by Country (2021-2026)
  5. 7.3.2 Global lrinotecan Sales by Country (2027-2032)
  6. 7.4 Global lrinotecan Sales Value by Country (2021-2032)
  7. 7.4.1 Global lrinotecan Sales Value by Country (2021-2026)
  8. 7.4.2 Global lrinotecan Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA lrinotecan Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA lrinotecan Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA lrinotecan Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada lrinotecan Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada lrinotecan Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada lrinotecan Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico lrinotecan Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico lrinotecan Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico lrinotecan Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany lrinotecan Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany lrinotecan Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany lrinotecan Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France lrinotecan Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France lrinotecan Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France lrinotecan Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. lrinotecan Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. lrinotecan Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. lrinotecan Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy lrinotecan Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy lrinotecan Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy lrinotecan Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain lrinotecan Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain lrinotecan Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain lrinotecan Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia lrinotecan Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia lrinotecan Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia lrinotecan Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands lrinotecan Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands lrinotecan Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands lrinotecan Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries lrinotecan Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries lrinotecan Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries lrinotecan Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China lrinotecan Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China lrinotecan Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China lrinotecan Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan lrinotecan Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan lrinotecan Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan lrinotecan Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea lrinotecan Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea lrinotecan Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea lrinotecan Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India lrinotecan Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India lrinotecan Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India lrinotecan Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia lrinotecan Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia lrinotecan Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia lrinotecan Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia lrinotecan Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia lrinotecan Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia lrinotecan Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil lrinotecan Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil lrinotecan Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil lrinotecan Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina lrinotecan Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina lrinotecan Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina lrinotecan Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile lrinotecan Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile lrinotecan Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile lrinotecan Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia lrinotecan Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia lrinotecan Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia lrinotecan Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru lrinotecan Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru lrinotecan Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru lrinotecan Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia lrinotecan Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia lrinotecan Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia lrinotecan Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel lrinotecan Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel lrinotecan Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel lrinotecan Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE lrinotecan Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE lrinotecan Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE lrinotecan Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey lrinotecan Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey lrinotecan Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey lrinotecan Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran lrinotecan Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran lrinotecan Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran lrinotecan Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt lrinotecan Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt lrinotecan Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt lrinotecan Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Actiza Pharmaceutical
  2. 8.1.1 Actiza Pharmaceutical Company Information
  3. 8.1.2 Actiza Pharmaceutical Business Overview
  4. 8.1.3 Actiza Pharmaceutical lrinotecan Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Actiza Pharmaceutical lrinotecan Product Portfolio
  6. 8.1.5 Actiza Pharmaceutical Recent Developments
  7. 8.2 Cipla
  8. 8.2.1 Cipla Company Information
  9. 8.2.2 Cipla Business Overview
  10. 8.2.3 Cipla lrinotecan Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Cipla lrinotecan Product Portfolio
  12. 8.2.5 Cipla Recent Developments
  13. 8.3 Getwell
  14. 8.3.1 Getwell Company Information
  15. 8.3.2 Getwell Business Overview
  16. 8.3.3 Getwell lrinotecan Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Getwell lrinotecan Product Portfolio
  18. 8.3.5 Getwell Recent Developments
  19. 8.4 Salius
  20. 8.4.1 Salius Company Information
  21. 8.4.2 Salius Business Overview
  22. 8.4.3 Salius lrinotecan Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Salius lrinotecan Product Portfolio
  24. 8.4.5 Salius Recent Developments
  25. 8.5 Taj Pharma
  26. 8.5.1 Taj Pharma Company Information
  27. 8.5.2 Taj Pharma Business Overview
  28. 8.5.3 Taj Pharma lrinotecan Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Taj Pharma lrinotecan Product Portfolio
  30. 8.5.5 Taj Pharma Recent Developments
  31. 8.6 West-ward Pharmaceuticals
  32. 8.6.1 West-ward Pharmaceuticals Company Information
  33. 8.6.2 West-ward Pharmaceuticals Business Overview
  34. 8.6.3 West-ward Pharmaceuticals lrinotecan Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 West-ward Pharmaceuticals lrinotecan Product Portfolio
  36. 8.6.5 West-ward Pharmaceuticals Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer lrinotecan Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer lrinotecan Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Teva
  44. 8.8.1 Teva Company Information
  45. 8.8.2 Teva Business Overview
  46. 8.8.3 Teva lrinotecan Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Teva lrinotecan Product Portfolio
  48. 8.8.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 lrinotecan Value Chain Analysis
  2. 9.1.1 lrinotecan Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 lrinotecan Sales Mode & Process
  6. 9.2 lrinotecan Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 lrinotecan Distributors
  9. 9.2.3 lrinotecan Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst